You are here

Jeong Mi Park, MD

Now that digital breast tomosynthesis (DBT) has gained FDA approval, many breast-imaging providers find themselves excited about the new technology, but facing uncertainty about reimbursement, implementation, and interpretation workflow. There remain a number of questions related to the display of (and approach to interpreting) DBT that need to be